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Abstract
Purpose To systematically review the previous studies and
current status of positron emission tomography (PET) molec-
ular imaging research in atypical parkinsonism.
Methods MEDLINE, ISI Web of Science, Cochrane Library,
and Scopus electronic databases were searched for articles
published until 29th March 2016 and included brain PET
studies in progressive supranuclear palsy (PSP), multiple sys-
tem atrophy (MSA), and corticobasal syndrome (CBS). Only
articles published in English and in peer-reviewed journals
were included in this review. Case-reports, reviews, and
non-human studies were excluded.
Results Seventy-seven PET studies investigating the dopami-
nergic system, glucose metabolism, microglial activation,
hyperphosphorilated tau, opioid receptors, the cholinergic sys-
tem, and GABAA receptors in PSP, MSA, and CBS patients
were included in this review. Disease-specific patterns of re-
duced glucose metabolism have shown higher accuracy than
dopaminergic imaging techniques to distinguish between par-
kinsonian syndromes. Microglial activation has been found in
all forms of atypical parkinsonism and reflects the known
distribution of neuropathologic changes in these disorders.
Opioid receptors are decreased in the striatum of PSP and
MSA patients. Subcortical cholinergic dysfunction was more
severe in MSA and PSP than Parkinson’s disease patients
although no significant changes in cortical cholinergic
receptors were seen in PSP with cognitive impairment.
GABAA receptors were decreased in metabolically affected
cortical and subcortical regions in PSP patients.
Conclusions PET molecular imaging has provided valuable
insight for understanding the mechanisms underlying atypical
parkinsonism. Changes at a molecular level occur early in the
course of these neurodegenerative diseases and PET imaging
provides the means to aid differential diagnosis, monitor dis-
ease progression, identify of novel targets for pharmacothera-
py, and monitor response to new treatments.
Keywords Atypical parkinsonism . Corticobasal syndrome .
Multiple system atrophy . Progressive supranuclear palsy .
Positron emission tomography
Introduction
Atypical parkinsonism includes a heterogeneous group of
movement disorders such as progressive supranuclear palsy
(PSP), multiple system atrophy (MSA), and corticobasal syn-
drome (CBS). These disorders are characterised by the pres-
ence of parkinsonian symptomatology with poor response to
levodopa and additional features beyond the classic
Parkinson’s disease (PD) presentation.
MSA is an adult-onset, fatal neurodegenerative disease
clinically characterized by a variable combination of progres-
sive autonomic failure, parkinsonian features, and cerebellar
and pyramidal features [1]. Its prevalence is about four to five
cases per 100,000, and patients usually die after a median
survival of 6 to 9 years [2]. MSA is pathologically
characterised by glial, α-synuclein-positive, cytoplasmic in-
clusion (GCI) in affected brain regions including striatonigral
and/or olivopontocerebellar systems [3].
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PSP is a neurodegenerative disorder with prevalence of five
to six cases per 100,000, with typical onset in the middle 60s
and median survival of 7 years [4]. PSP is currently classified
among the group of tau-positive frontotemporal lobar degen-
erations [5]. It is characterized clinically by the presence of
symmetrical akinetic–rigid parkinsonian syndrome,
supranuclear gaze palsy, early postural instability with falls
backwards, subcortical dementia, dysarthria, and dysphagia
[6, 7]. The pathological hallmark of PSP is accumulation of
abnormal tau protein (4-repeat tau) in subcortical nuclei neu-
rons forming the neurofibrillary tangles and glial cells as tuft-
ed astrocytes and oligodendrogial inclusions [8, 9].
CBS is a rare neurodegenerative disorder with prevalence
ranging from 0.2 to four cases per 100,000 and an average
time from symptoms onset to death of 7 years [10, 11]. The
core clinical features of CBS include asymmetric rigidity and
apraxia together with other features such as cortical sensory
loss, alien limb behaviour, gaze palsy, atypical tremor, and
dementia [12, 13]. CBS is characterized neuropathologically
by deposits of 4-repeat tau in cortical and striatal neurons and
glia, forming astrocytic plaques [14].
Early diagnosis of these three atypical parkinsonian syn-
dromes is still challenging with 24 % of the patients being
misdiagnosed [15]. Currently, there are no biomarkers or dis-
ease modifying therapy for these three disorders, while symp-
tomatic treatment is very limited. Positron emission tomogra-
phy (PET) molecular imaging is a powerful in vivo tool for
investigating brain function such as metabolism, receptor, and
enzyme distributions. PET is an analytical imaging method
and has the potential to give both structural and kinetic infor-
mation and in comparison with other imaging techniques,
provides high sensitivity and temporal resolution [16]. In re-
cent decades, PET imaging research has been employed ex-
tensively in movement disorders and has significantly contrib-
uted to progress in understanding atypical Parkinsonism
(Table 1) [17–22]. Despite this progress only little of this
understanding has been translated into the clinical setting
[23, 24].
In this article, we aimed to review systematically the pre-
vious studies and current status of PET molecular imaging
research in atypical parkinsonism. We reviewed disease-
related patterns of PET molecular changes, their clinical cor-




MEDLINE, ISI Web of Science, Cochrane Library, and
Scopus databases electronic databases were searched for arti-
cles in English published until 29th March 2016. Gray
literature (i.e., abstracts or conference proceedings), reviews,
case-reports, and non-humans studies were not considered as a
priority asset of our systematic review. Studies were identi-
fied, combining the following major Medical Subject
Headings: “Atypical Parkinsonism” or “Corticobasal
Degenerat ion” or “Multiple System Atrophy” or
“Progressive Supranuclear Palsy” and “PET” combined with
text and keywords (MEDLINE, for example): ([“Atypical
Park inson ism” , MeSH Terms, OR “Progress ive
Supranuclear Palsy” OR “Richardson-Steele-Olszewski syn-
drome” OR “Multiple System Atrophy”, MeSH Terms, OR
“Shy-drager syndrome” OR “olivopontocerebellar atrophy”
OR “striatonigral degeneration” OR “Corticobasal
Ganglionic Degeneration” OR “Corticobasal Degeneration”]
AND ]“Positron-Emission Tomography”, MeSH Terms, OR
“positron emission tomography” OR “PET”]). Additional el-
igible studies were identified screening the reference lists of
studies included in our analysis.
Inclusion criteria
All selected titles and abstracts were independently reviewed
by two authors (FN, MP). Studies were excluded if the title
and/or abstract were not appropriate for the aim of the review.
Full texts were subsequently obtained for eligible studies or
when the relevance of an article could not be certainty exclud-
ed. Selected studies were eligible if they met the following
criteria: 1) cross-sectional, case control, or longitudinal brain
PET studies including PSP, MSA, and CBS patients; 2) pub-
lished in peer-reviewed journals. Reviews, case-reports and
non-human studies were excluded. PET measures included
the following radioligands: [11C]raclopride (dopamine D2 re-
ceptors), [11C]DTBZ [vesicular monoamine transporter type-2
(VMAT2)]; [18F]FP-CIT [dopamine transporter (DAT)];
H2
15O (brain metabolism); [11C]PK11195 (microglial activa-
tion), [18F]FDG (glucose metabolism); [18F]FDDNP
(hyperphosphorilated tau); [11C]PiB (amyloid deposition);
[11C]flumazenil (GABAA receptors); [
11C]diprenorphine
(opioid receptors); [11C]PMP [acetylcholinesterase (AChE)
activity]; and [11C]NMPB [muscarinic acetylcholine receptors
(mAChRs)]. A total of 77 PET studies were identified and
reviewed in this article.
Results
Brain metabolism
[18F]FDG PET has been employed to assess regional cerebral
glucose metabolism as a marker of neuronal activity and neu-
rodegeneration in atypical parkinsonism. In MSA, [18F]FDG
PET studies have shown reduced brain metabolism in the
frontal cortex, striatum, cerebellum, and brainstem [25–32].
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Decreased [18F]FDG uptake in putamen, brainstem, or cere-
bellum is part of the diagnostic criteria for possible MSA [33].
Patients with a diagnosis of possible MSA showed greater
decreases in glucose metabolism than patients with probable
MSAwho had severe autonomic dysfunction [34]. These find-
ing suggest that the pattern of glucose metabolism in probable
MSA with predominant involvement of the autonomic ner-
vous system, may differ from that of possible MSA, which
mainly involves the striatonigral or olivopontocerebellar sys-
tems. Glucose hypometabolism mainly occurs in the bilateral
putamen in parkinsonian-type and in the bilateral cerebellum
in cerebellar-type MSA patients [35] in line with the neuro-
pathologic feature of these two MSA subtypes [36]. MSA
patients showed also a different pattern in metabolic changes
at different stages of the disease suggesting that cortical
hypometabolism begins in the frontal cortex and spreads to
the parieto-temporal cortex [37]. Decreases in cerebellar
glucose metabolism occur early in the course of the disease
and contribute to cerebellar symptoms, whereas motor symp-
toms precede putaminal hypometabolism [37]. Cerebellar
hypometabolism is associated with the severity of ataxia,
whereas decreased glucose metabolism in the brainstem cor-
related with the severity of autonomic dysfunction [31]. Using
H2
15O PET, Payoux and colleagues [38] investigated patterns
of motor activation before and after an acute levodopa chal-
lenge in MSA, PD patients, and a group of healthy controls.
Before levodopa challenge, MSA patients showed greater ac-
tivation of left superior parietal areas and lower bilateral cer-
ebellar activation than healthy controls. In comparison with
PD patients, MSA patients had less bilateral cerebellar and
greater supplementary motor and left superior parietal activa-
tion [38]. Following levodopa challenge,MSA patients exhib-
ited reduced activation in anterior cingulate, whereas patients
with PD had greater activation in the right cerebellum. These
Table 1 Main PET molecular imaging changes in multiple system sclerosis, progressive supranuclear palsy, and corticobasal syndrome
MSA PSP CBS
Brain Metabolism Reduced brain metabolism in bilateral
putamen, cerebellum, and brainstem
Reduced brain metabolism in bilateral
medial frontal cortex, premotor areas,
prefrontal areas, striatum (caudate in
particular), thalamus, and brainstem
Asymmetric reduced brain
metabolism contralateral to the
most affected side involving
parietal cortex, primary
sensorimotor cortex, the medial
and lateral premotor areas,
striatum, and thalamus
Dopaminergic system Reduced [18F]dopa uptake in caudate,
putamen, ventral striatum, globus
pallidus, and red nucleus.
Reduced [11C]DTBZ uptake in caudate and
putamen (also cerebellum in MSA-C)
Reduced [18F]dopa and [18F]FP-CIT uptake
in caudate, putamen (caudate and
anterior putamen affected at the same
level as the posterior putamen)
Asymmetric decreased in
[18F]Fdopa uptake in the caudate
and the putamen contralateral to
the most affected side
Decreased striatal D2 receptor density Decreased striatal D2 receptor density
Microglial activation Increased [11C]PK11195 binding was also
found in the dorsolateral prefrontal
cortex, caudate, putamen, pallidum,
thalamus, substantia nigra, and pons
Increased [11C]PK11195 binding in
caudate, putamen, pallidum, substantia
nigra, midbrain, thalamus, cerebellum,
and frontal lobe
Increased [11C]PK11195 binding in
caudate, putamen, substantia
nigra, and frontoparietal cortex
Tau deposition Increased [18F]FDDNP binding in
subthalamic area, midbrain region, and
cerebellar white matter. Increased
[18F]FDDNP binding in neocortical
regions (frontal lobe, temporal lobe an
posterior cingulate gyrus) only in PSP
subjects with more severe disease
Opioid system Decreased opioid receptors in putamen, but
not caudate of MSA-P
Decreased opioid receptors in both caudate
and putamen
Decreased opioid receptors in both caudate
and putamen in MSA-C
GABAergic system Decreased [11C]flumazenil binding in
hypometabolic cortical regions
Cholinergic markers Decreased cortical and subcortical AChE
activity in MSA-P
No significant changes in cortical mAChR
levels in PSP patients with cognitive
impairment.
Decreased subcortical AChE activity with
greater involvement of the pontine
cholinergic group.
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different patterns of activation may be explained by the pres-
ence of cerebellar dysfunction in MSA patients and activation
of frontoparietal cortical areas may be seen as compensatory
mechanism [38].
In PSP, [18F]FDG PET studies showed a significant
hypometabolism in bilateral medial frontal cortex involving
mainly the anterior and mid cingulate gyri, the supplementary
motor area (SMA), the ventro- and dorsolateral premotor
areas, the prefrontal areas, the striatum (caudate, in particular),
thalamus, and the brainstem [39–46]. Different patterns of
glucose metabolism has been observed in PSP subtypes
[44]. Richardson’s syndrome (RS) patients showed pro-
nounced thalamic and frontal cortex hypometabolism, where-
as PSP-parkinsonism (PSP-P) patients had more significant
putaminal hypometabolism Moreover, the putamen/thalamus
[18F]FDG uptake ratio was able to discriminate between PSP-
P and RS patients [47]. Piccini and colleagues [48] studied
three affected patients and their asymptomatic relatives from
two kindreds with familial PSP. Striatal [18F]FDG uptake was
reduced in PSP patients in agreement with findings reported
for sporadic PSP [48]. Moreover, 33 % of asymptomatic rel-
atives showed cortical and subcortical hypometabolism sug-
gesting the presence of subclinical PSP [48]. [18F]FDG PET
was used to investigate neural correlates of PSP symptoms
[49–52]. A PET study investigated the brain network relevant
to postural imbalance and falls in a cohort of 16 PSP patients
[50]. Decreased glucose metabolism in the thalamus and in-
creased in the precentral gyrus were associated with severity
of postural instability and frequency of falls suggesting that
thalamo-cortical circuits are critical for postural imbalance in
PSP [50]. Another study from the same group assessed loco-
motor network in 12 PSP patients [51]. PSP patients
underwent a [18F]FDG PET at rest and during walking.
Hypometabolism was observed at rest in the prefrontal cortex,
the subthalamic nucleus, and the pedunculopontine/cuneiform
nucleus complex of PSP patients compared to the group of
healthy controls [51]. The severity of gait disorder was asso-
ciated with decreases in glucose metabolism in the prefrontal
cortex and subthalamic nucleus. During walking, PSP patients
showed decreased [18F]FDG uptake in the of the indirect lo-
comotor pathway via the prefrontal cortex–subthalamic nucle-
us–pedunculopontine/cuneiform nucleus loop, whereas acti-
vation of the direct locomotor pathway from primary motor
cortex to the spinal cord was observed in PSP patients [51].
These findings suggest that gait dysfunction in PSP is related
to impairment of the indirect, modulatory prefrontal–subtha-
lamic–pedunculopontine loop of locomotor control. The in-
crease in the direct locomotor loop may be seen as a compen-
satory mechanism or contribute to the stereotyped gait pattern
in PSP. Oculomotor dysfunction was also associated with re-
duced regional glucose metabolism in PSP patients [52]. In
specific, hypometabolism in the anterior cingulate gyrus was
associated with downward gaze palsy. Reduced [18F]FDG
uptake in the rostral cerebellum was positively correlated with
velocity of horizontal saccades and decreased glucose metab-
olism in the oculomotor vermis was associated with peak ve-
locity of the optokinetic reflex. Smooth pursuit eye movement
was correlated with hypometabolism in the inferior parietal
and temporal regions and frontal eye field [52]. Reduced glu-
cose metabolism in the frontal cortex was associated with
worse Mini Mental Status Examination (MMSE) scores in
16 PSP patients the presence of frontal lobe dysfunction in
PSP [49]. Frontal brain regions and in specific cingulate gyrus
hypometabolism is also a feature of Frontotemporal Dementia
[53–57]. Hypoperfusion of the midcingulate cortex was re-
ported in both PSP and FTD tau patients and correlated with
executive dysfunction [58]. In specific, in PSP patients
showed hypoperfusion of the posterior part of the
midcingulate gyrus, which was associated with worse perfor-
mance at the Stroop III and Weigl tests [58].
In CBS patients, [18F]FDG PET has shown a characteristic
asymmetric pattern of impaired glucose metabolism contralat-
eral to the most affected side involving the parietal cortex
(usually most prominent), the primary sensorimotor cortex,
the medial and lateral premotor areas, the striatum, and the
thalamus [35, 44, 46, 56, 59–66]. Cortical metabolic asymme-
try was also associated with asymmetries in thalamic
[18F]FDG uptake suggesting the presence of cortico-
thalamic metabolic asymmetry, which is in agreement with
focal neuropathological changes reported in CBS [59].
[18F]FDG PET was used to investigate the brain networks
underlying upper limb praxis processing in a cohort of prob-
able CBS [67]. Anterior cingulate hypometabolism was ob-
served in those CBS patients who performed below the cut-off
score at the upper limb apraxia assessment [67]. Moreover,
CBS patients who were unable to correct their errors at the
same rate as controls showed hypometabolism in superior
parietal lobule and SMA suggesting that different neural net-
works are involved in distinct aspects of the upper limb aprax-
ia in CBS [67].
Cerebral glucose metabolism patterns may be useful to
differentiate atypical parkinsonian syndromes. Disease-
specific patterns of reduced metabolic activity were found in
MSA (bilateral putamen, pons, and cerebellum), PSP (cau-
date, thalamus, midbrain, and prefrontal cortex), CBS (asym-
metrical cortical regions and basal ganglia) [30, 32, 35, 44, 46,
65, 68–72]. The most consistent difference in metabolic activ-
ity between atypical parkinsonism and PD is decreased striatal
glucose metabolism in atypical parkinsonism patients [30, 32,
35, 42, 47, 56, 68, 72], which is in agreement with post-
mortem studies showing post-synaptic striatal neuronal loss
in MSA, PSP, and CBS, but not in PD [73].
Specific voxel-based metabolic covariance patterns were
able reliably to differentiate PSP, MSA, and CBS patients
from healthy controls [66, 69]. An MSA-related pattern was
characterized by a significant pattern ofmetabolic decreases in
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the putamen and the cerebellum, whereas a PSP-related pat-
tern showed hypometabolism in the brainstem, medial thala-
mus, caudate nuclei, and medial frontal cortex [69]. A CBS-
related pattern involves asymmetrical reductions contralateral
to the more affected side in the cerebrum, lateral parietal and
frontal regions, and thalamus, with relative bilateral increases
in occipital regions [66]. The CBS-related pattern distin-
guished CBS from MSA, but not PSP patients because of
the 24 % overlap existing in CBS and PSP spatial metabolic
patters [66]. However, by measuring the degree of hemispher-
ic asymmetry at the network level and comparing with the
PSP-related pattern, the authors were able to discriminate be-
tween CBS and PSP with 92–94 % specificity [66]. The same
group developed an automated image-based classification
procedure to differentiate patients with PD, MSA, and PSP
[45]. This method showed high sensitivity and specificity in
distinguishing these three diseases and may be useful in im-
proving diagnostic accuracy [45]. Visual and SPM analysis of
[18F]FDG PET showed also higher sensitivity (90–95 %) in
differentiating MSA from PD patients than visual MRI anal-
ysis [74, 75]. [18F]FDG PET studies compared cerebral glu-
cose metabolism of PSP and CBS patients. The most consis-
tently findings were a significantly asymmetrical
hypometabolism of the parietal lobe and the primary sensori-
motor cortex in CBS patients, while PSP patients usually
showed a significantly lower bilateral glucose metabolism of
the anterior cingulate gyrus and the upper brainstem [41, 42,
44, 61, 64]. Asymmetric presentation of clinical symptoms in
PSP patients may make differential diagnosis between PSP
and CBS difficult. A recent PETstudy investigated differences
in glucose metabolism between PSP with asymmetric clinical
symptoms, PSP with symmetric presentation, and CBS pa-
tients [76]. PSP patients with asymmetrical clinical symptoms
showed significant asymmetrical hypometabolism contralat-
eral to the clinically most affected side in ventrolateral thala-
mus, middle cingulate gyrus, and sensorimotor cortex com-
pared to PSP patients with symmetrical symptoms [76]. In
comparison with CBS patients, PSP patients with asymmetri-
cal and symmetrical clinical symptoms showed similar bilat-
eral medial frontal hypometabolism [76]. Asymmetric parietal
hypometabolism extending into the premotor cortex contralat-
eral to the clinically most affected side was observed in CBS
patients [76]. These findings suggest that disease-specific pat-
terns of [18F]FDG uptake may also help with the differential
diagnosis between PSP patients with asymmetrical symptoms
and CBS.
[18F]FDG PET has been used to test the efficacy of treat-
ment in atypical parkinsonism. A small-randomised placebo
controlled clinical trial assessed the effects of physostigmine,
a cholinesterase inhibitor, on clinical symptoms and brain glu-
cosemetabolism in six PSP patients [77]. Intravenous infusion
of physostigmine increased by 8 to 32 % regional glucose
metabolism and improved ocular movements and attention
at the cognitive test [77]. These findings suggest that enhance-
ment of cerebral cholinergic transmission in PSP using phy-
sostigmine could increase glucose entry into the brain [77].
Dopaminergic system
PETstudies using [18F]dopa, [18F]FP-CIT, or [11C]DTBZ pro-
vided information about the dysfunction of brain monoamin-
ergic projections in patients with atypical parkinsonism. In
MSA, [18F]dopa uptake was significantly decreased in the
caudate, putamen, ventral striatum, and globus pallidus
reflecting loss of dopaminergic innervations from the
substantia nigra [68, 78–82]. Moreover, significantly de-
creases in [18F]dopa uptake were found in the red nucleus of
MSA patients compared to healthy controls suggesting dys-
function of the midbrain tegmentum, locus coeruleus, and
median raphe which project to this region [81]. Caudate-
putamen index, reflecting differences in the uptakes in the
caudate and putamen divided by the caudate uptake, showed
greater caudate involvement in MSA in comparison with PD
patients suggesting that caudate-purtamen index may be use-
ful in discriminating MSA from PD [80].
Pre-synaptic dopaminergic dysfunction is also associat-
ed to clinical symptoms. In specific, reduced [18F]dopa
uptake in the locus coeruleus correlated with the severity
of orthostatic hypotension in MSA patients [81] and
striatal [18F]dopa decreases was associated with worse lo-
comotor disability [78]. A recent [18F]FP-CIT PET study
has investigated differences in dopamine transporter (DAT)
in three different phenotypes of MSA divided according to
different patterns of glucose metabolism: MSA-Pm (only
striatal hypometabolism), MSA-Cm (only cerebellar
hypometabolism), and MSA-mixedm (both striatal and cer-
ebellar hypometabolism) [83]. A significant difference in
striatal DAT binding was found among the metabolic phe-
notypes. A marked decreased striatal DAT binding with
higher anteroposterior and ventrodorsal gradient was ob-
served in the MSA-Pm and MSA-mixedm groups, whereas
less decrease was seen in the MSA-Cm group [83]. VMAT2
density was significantly decreased in the caudate and pu-
tamen in MSA patients [84, 85] and in the cerebellum of
MSA-C patients [85]. Moreover, significant correlations
were found between decreased striatal binding and the se-
verity of parkinsonian features and between reduced cere-
bellar binding and severity of cerebellar dysfunction [85].
These findings suggest a differential severity of degenera-
tion of dopaminergic nigrostriatal and non-dopaminergic
monoaminergic cerebellar systems in MSA-P and MSA-C
subtypes. Decreased striatal [11C]DTBZ binding was also
associated with the severity of REM sleep behaviour dis-
order (RBD) in 13 patients with probable MSA [86].
Decreased striatal [18F]Fdopa uptake correlated with the
severity of extrapyramidal symptoms in MSA [31].
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In PSP, [18F]dopa uptake was significantly decreased in
both caudate and putamen. Differently from PD patients
where a rostro-caudal putamen gradient of dopaminergic dys-
function is observed, in PSP, [18F]dopa uptake in the caudate
and anterior putamen was depressed to the same level as that
in the posterior putamen [78]. This pattern of presynaptic de-
generation was also observed with [18F]FP-CIT PET [87].
Patients with PSP showed more prominent and earlier DAT
losses in the anterior caudate and ventral putamen compared
to PD patients [87]. Moreover, by applying discriminant func-
tion analysis Burn and colleagues [88] found that [18F]dopa
uptake can reliably discriminate between normal subjects and
parkinsonian patients, but differential diagnosis between PD,
MSA, and PSP remained difficult. In CBS, [18F]Fdopa was
markedly reduced with an asymmetry in the caudate and the
putamen contralateral to the most affected side [61, 89].
However, single positron emission tomography (SPECT)
studies have shown that nigrostriatal degeneration may occur
at later stages of the disease [90–95] after cortical
hypometabolism took place [93]. In 23 early to mid stages,
CBS patients, of whom one had post-mortem confirmed diag-
nosis of definite CBS, striatal presynaptic DAT uptake was
mildly decreased with 39 % of the subjects presenting no
dopaminergic deficits [92]. Moreover, postsynaptic dopamine
D2 receptor density was preserved [92].
Post-synaptic dopaminergic function has been investigated
in atypical parkinsonism with [11C]raclopride PET. Studies
have shown significant decreases of striatal dopamine D2 re-
ceptor density in patients with MSA-P and PSP compared to
PD and healthy controls [43, 68, 96–98]. Striatal antero-
posterior gradient of [11C]raclopride binding was significantly
higher in MSA-P than in PD patients [68, 98]. Van Laere and
colleagues [98] showed that combined analysis of striatal
binding and regional influx of [11C]raclopride may aid in dif-
ferentiating PD fromMSA-P patients. PETwith [18F]DMFP, a
fluorine-18 dopamine D2 radioligand, showed reduced striatal
uptake inMSA and PSP patients compared to healthy controls
and PD patients [99]. Receiver operating characteristic (ROC)
curve analysis showed a specificity, sensitivity and accuracy
of 100 %, 74 % and 86 %, respectively, of [18F]DMFP mo-
lecular imaging for the differential diagnosis of atypical par-
kinsonism and PD [99].
Microglial activation
Microglia constitute about 10 % of glial cells and are primary
mediators of neuroinflammation that respond to pathological
changes in the brain producing an excess of various pro-
inflammatory cytokines such as TNF-a and IL-1β [100].
These cytokines in turn cause further activation of microglia,
resulting in a self-propagating inflammatory cascade, leading
to neuronal death and contributing to pathogenesis of atypical
parkinsonism [101, 102]. When microglia become activated
they overexpress the 18-kd translocator protein (TSPO),
which can be detected in vivo with PET and selective
radioligands [103, 104]. PET with [11C]PK11195 has been
employed to study a small cohort of patients with PSP,
MSA, and CBS [105–107]. Increased [11C]PK11195 binding
was observed in the caudate, putamen, pallidum, substantia
nigra, midbrain, thalamus, cerebellum, and frontal lobe in four
PSP patients [107]. In the two patients who were rescanned
after 6–10 months, microglial activation remained stable al-
though patients progressed clinically [107]. Similarly, four
patients with CBS showed increased [11C]PK11195 binding
in caudate, putamen, substantia nigra, and frontoparietal cor-
tex [106].
Increased [11C]PK11195 binding was also found in the
dorsolateral prefrontal cortex, caudate, putamen, pallidum,
thalamus, substantia nigra, and pons of five MSA patients
[105]. Moreover, increased pontine microglial activation cor-
related with MRI measures of tissue damage such as regional
apparent diffusion coefficient, although was not associated
with putaminal water diffusivity changes in patients with
MSA-P and PSP [108]. [11C]PK11195 PET has also been
used to monitor the efficacy of anti-inflammatory agents ther-
apies in atypical parkinsonism. In a randomized placebo-
controlled trial assessing the efficacy of minocycline in pa-
tients with MSA, decreased [11C]PK11195 binding was ob-
served following treatment, although no clinical benefit of
minocycline was found in the trial [109]. Moreover, clinical
assessments did not correlate with [11C]PK11195 binding.
This discrepancy may be due to the small number of partici-
pants or to the short duration and/or weakness of the
minocycline effects that may be unable to inhibit the pathways
downstream of microglial activation leading to the expression
of clinical symptoms.
Other systems
Using PET with [11C]diprenorphine, Burn and colleagues
[110] investigated the pattern of striatal opioid receptor densi-
ty in the brain ofMSA-P, PSP, and PD patients. They found no
significant differences in opioid receptor density in PD pa-
tients, whereas decreased [11C]diprenorphine binding was ob-
served in the putamen, but not caudate of MSA-P patients and
opioid receptor decreases were seen in both caudate and pu-
tamen in PSP patients [110]. MSA-C patients showed 85–
88 % decreases in opioid receptor density in both caudate
and putamen [79]. Foster and colleagues [111] explored the
integrity of GABAergic neurons in metabolically affected cor-
tical regions in PSP patients. A reduction of 13 % in
[11C]flumazenil binding was found in hypometabolic cortical
regions, but not in subcortical nuclei, suggesting that loss of
cortical neurons containing benzodiazepine receptors may
contribute to cerebral cortical hypometabolism in PSP [111].
One PET study using [11C]NMPB, a radioligand for
Eur J Nucl Med Mol Imaging
mAChRs, has studied cholinergic dysfunction in a cohort of
PSP patients with cognitive impairment [112]. Differently to
PD, PSP patients showed no significant changes in cortical
mAChR levels, and there was no correlation between
[11C]NMPB binding and cognitive impairment as measured
by the MMSE scores [112]. These findings suggest that dys-
function of the cholinergic system may not play a role in
cognitive impairment in PSP. PET with [11C]PMP showed
significant decreases in cortical AChE activity in MSA-P pa-
tients at a similar level of those seen in PD patients [113]. In
MSA-P and PSP, subcortical cholinergic activity was more
decreased than in PD patients with greater involvement of
the pontine cholinergic group [113]. Since pontine cholinergic
group plays an important role in modulating motor function
and in specific gait, this finding may account for greater gait
impairment in MSA-P and PSP than PD.
Conclusion
In recent decades, PET molecular imaging has provided a
better understanding of the pathophysiological mechanisms
underlying atypical parkinsonism. However, most of the
PET imaging studies was performed in patients with probable
diagnosis while data in possible MSA or PSP are limited.
Moreover, none of the available PET techniques has shown
to be a reliable and early biomarker to differentiate between
atypical parkinsonism and PD and monitor disease progres-
sion and response to treatment. [18F]FDG PET has shown
higher accuracy than dopaminergic imaging techniques to dis-
tinguish among parkinsonian syndromes and in differentiating
between atypical parkinsonism. A concomitant loss of pre-
and post-synaptic terminals in atypical parkinsonism could
explain the limited efficacy of levodopa replacement therapy
in these degenerative disorders. [11C]PK11195 PET has
shown different patterns of microglial activation in atypical
parkinsonism, which reflects the known pathology in these
disorders. However, [11C]PK11195 shows high level of non-
specific binding and a poor signal-to-noise ratio [114], which
complicates its quantification; moreover, test–retest data in
control subjects showed only moderate intra-individual repro-
ducibility [115]. Second generation TSPO ligands for PET
imaging may provide a better quantification of microglial ac-
tivation in atypical parkinsonism. Additionally, astroglial ac-
tivation plays a key role in the initiation and progression of
atypical parkinsonism. PET with specific radioligands
targeting astroglial activation may provide new insight in the
molecular mechanisms underlying the pathogenesis of these
disorders. Recently, a number of fluorinated radioligands have
shown in vitro and in vivo ability to label tau aggregates and to
possess selectivity for tau over β-amyloid aggregates
[116–120]. In vivo imaging of tau aggregates with PET may
aid in early diagnosis of CBS and PSP and provide a tool to
monitor disease progression. Additionally, tau PET can also
serve as a potential biomarker of disease progression and an
indicator of treatment efficacy for interventions aimed at
preventing tau aggregate formation.
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